THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST There’s some good news for a company and a therapeutic approach that CIRM has been supporting for many years. In September 2018, CRISPR Theraputics and ViaCyte entered a partnership to discover, develop and market gene-edited stem cell-derived therapies to treat type 1 diabetes (T1D). Today, they may stand … Continue reading First Patient Dosed in Phase 1 Clinical Trial for T1D
Phase 1 clinical trial
Why “Right to Try” laws are more feel good than do good
L to R: Don Gibbons, CIRM; Jeanne Loring; Beth Roxland; Aaron Levine In the last few years some 24 states have approved so-called “Right to Try” laws. These are intended to give terminally ill patients faster and easier access to experimental therapies. But a panel of experts at the World Stem Cell Summit in Atlanta … Continue reading Why “Right to Try” laws are more feel good than do good
The Stem Cellar 